Skip to main content
Home / News / Certara Acquires Integrated Nonclinical Development Solutions

Certara Acquires Integrated Nonclinical Development Solutions

Expands software portfolio and nonclinical drug development expertise

PRINCETON, N.J.— Jan 5, 2022– Certara, Inc., a global leader in biosimulation, today announced the acquisition of Integrated Nonclinical Development Solutions, Inc. (INDS), a company that provides the SEND Explorer® software and drug development consulting with a focus on nonclinical and toxicology support. Financial terms of the transaction were not disclosed.

“We are excited to welcome INDS to Certara,” said Patrick F. Smith, president of Integrated Drug Development at Certara.  “INDS’ unique combination of software and deep expertise in toxicology and nonclinical development is complementary to Certara’s offerings.  INDS is a great addition to helping our clients bridge the translational gap between the preclinical and clinical phases, a pivotal checkpoint in the drug development process.”

Founded in 2007, INDS develops and supports the SEND Explorer software, a validated, web-based application that delivers advanced viewing, data summarization and visualization capabilities for nonclinical study data produced in Standard for Exchange of Nonclinical Data (SEND) format.  SEND Explorer makes study data accessible and easy to analyze for decision-making and allows biopharmaceutical companies to visualize SEND datasets for investigational new drug (IND) submissions to the US FDA and other regulatory agencies.

Furthermore, INDS’ team of nonclinical development experts provides drug development program designs and management, safety issue analysis and resolution strategies, and regulatory submission preparation.  The team consists of board-certified toxicologists, veterinarians, and software developers with more than 100 years of combined experience in the pharmaceutical industry. 

“We are thrilled to join Certara and be part of a bigger future together,” said James R. Herman, president of INDS.  “This is a great fit on multiple levels – technology, talent and mission to accelerate medicines.  We are enthusiastic about the opportunities this combination presents for INDS and our clients.”

To learn more, please contact

About Certara

Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Certara Contact:

Jieun Choe
Chief Strategy and Marketing Officer